Rhenman & Partners Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30,099	Closed	-$420K	–	112
2017 Q2	$420K	Hold	30,099	–	–	0.06%	91
2017 Q1	$513K	Hold	30,099	–	–	0.08%	85
2016 Q4	$310K	Hold	30,099	–	–	0.06%	95
2016 Q3	$304K	Hold	30,099	–	–	0.05%	95
2016 Q2	$338K	Buy	+30,099	New	+$383K	0.06%	93

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Rhenman & Partners Asset Management's CNCE Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2017, closing a stake of 30,099 shares — an estimated $420K sold.

Rhenman & Partners Asset Management first reported a position in CNCE in Q2 2016 and held it in 5 quarters. The position peaked at $513K in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 30,099 Concert Pharmaceuticals, Inc. shares in Q3 2017, an estimated $420K.
Rhenman & Partners Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2016 and held it in 5 quarters.
Rhenman & Partners Asset Management's Concert Pharmaceuticals, Inc. position peaked at $513K in Q1 2017.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.